Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05761899 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of PMT Therapy of hPAP
A Phase 1 study of Hereditary Pulmonary Alveolar Proteinosis, sponsored by Children's Hospital Medical Center, Cincinnati.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT05761899: Recruiting Phase 1 study of Hereditary Pulmonary Alveolar Proteinosis, sponsored by Children's Hospital Medical Center, Cincinnati.
NCT05761899 is a Phase 1 study of Hereditary Pulmonary Alveolar Proteinosis that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05761899, a Phase 1 study of Hereditary Pulmonary Alveolar Proteinosis, is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
The major goal of this study is to evaluate a new type of cell transplantation therapy for individuals with hereditary PAP, study a new treatment that may be useful for treatment of other diseases, and research mechanisms that drive the development and function of lung macrophages.
Primary Outcome
Number of patients with a CTCAE grade 3 or 4 AE in clinical history findings, physical exam findings, vital signs, clinical laboratory values, pulmonary function data, cardiac function, chest x-ray, chest CT at any time during the study period after initiation of PMT Therapy
Conditions Studied
Interventions
- COMBINATION_PRODUCT Gene-Corrected Macrophages administered by bronchoscopic instillation
Study Locations (1)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2023-06-26 |
| Est. Completion | 2038-10-01 |
| Phase | Phase 1 |
What NCT05761899 shows while recruiting
NCT05761899 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Hereditary Pulmonary Alveolar Proteinosis appearing as the primary indexed condition, and to 1 intervention - of which Gene-Corrected Macrophages administered by bronchoscopic instillation is the first listed.
NCT05761899 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05761899 about?
NCT05761899 is a clinical study titled "Safety and Efficacy of PMT Therapy of hPAP". The major goal of this study is to evaluate a new type of cell transplantation therapy for individuals with hereditary PAP, study a new treatment that may be useful for treatment of other diseases, and research mechanisms that drive the development and function of lung macrophages.
What is the current status of trial NCT05761899?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2023-06-26. Estimated completion is 2038-10-01.
What conditions does trial NCT05761899 study?
This clinical trial studies the following conditions: Hereditary Pulmonary Alveolar Proteinosis.
What interventions are being tested in trial NCT05761899?
The interventions under investigation include: Gene-Corrected Macrophages administered by bronchoscopic instillation (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05761899?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05761899 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05761899's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI